Syncom at Drug Discovery Chemistry 2015

DCH_header

Syncom will be present at Drug Discovery Chemistry, April 21–23, 2015 at booth #27, Hilton San Diego Resort & SPA, San Diego, CA, USA.

Also a poster will be presented, entitled:

DESIGN, SYNTHESIS AND SAR OF SOLUBLE 4-FLUOROPHENYL-IMIDAZOLE P38-ALPHA MAPK, CK1-DELTA AND JAK2 KINASE INHIBITORS.

Introduction of the poster:

The p38α MAPK and JAK signaling pathways are elevated or dysregulated in many inflammatory and autoimmune diseases such as rheumatoid arthritis, osteoarthritis, asthma, chronic obstructive pulmonary disease, inflammatory bowel disease, Crohn’s disease, acute coronary syndrome, multiple sclerosis, diabetes mellitus and cancer. The CK1δ signaling pathway is involved in circadian rhythm and DNA damage control.

p38_MAPK_and_JAK_signaling_pathwaysThe 4-fluorophenyl-imidazole scaffold is present in p38α MAP kinase inhibitors SB203580, JNJ 7583979, caseine kinase I delta (CK1δ) inhibitors PF-670462, CKP138, as well as in a pyridone pan-JAK inhibitor (Fig. 1). Despite the potential benefits none of these imidazoles has reached the clinic yet because of toxicity problems, related with off-target selectivity and their highly lipophilic character1.